Publications by authors named "Russ B Altman"

Are you Russ B Altman?   Register this Author



Population-specific single-nucleotide polymorphism confers increased risk of venous thromboembolism in African Americans.
Mol Genet Genomic Med 2016 Sep 21;4(5):513-20. Epub 2016 Jun 21.
Department of GeneticsStanford University School of MedicineStanfordCalifornia94305; Department of BioengineeringStanford University School of MedicineStanfordCalifornia94305.

PharmGKB summary: very important pharmacogene information for RYR1.
Pharmacogenet Genomics 2016 Mar;26(3):138-44
Departments of aGenetics bBioengineering, Stanford University, Stanford cChildren's Hospital Oakland Research Institute and UCSF, Oakland, California dDepartment of Medicine, University of North Dakota, Fargo, North Dakota eIMAGENETICS, Sanford Healthcare, Sioux Falls, South Dakota, USA.

PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics.
Pharmacogenet Genomics 2015 Dec;25(12):622-30
Departments of aGenetics bBioengineering, Stanford University, Stanford, California cDepartment of Anesthesiology dMoffitt Cancer Center, DeBartolo Family Personalized Medicine Institute, Tampa, Florida, USA eGenomics England, Queen Mary University of London, London, UK.

Sequence to Medical Phenotypes: A Framework for Interpretation of Human Whole Genome DNA Sequence Data.
PLoS Genet 2015 Oct 8;11(10):e1005496. Epub 2015 Oct 8.
Stanford Center for Inherited Cardiovascular Disease, Stanford University, Stanford, California, United States of America; Stanford Cardiovascular Institute, Stanford University, Stanford, California, United States of America; Division of Cardiovascular Medicine, Stanford University, Stanford, California, United States of America; Department of Genetics, Stanford University, Stanford, California, United States of America.

PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses.
Pharmacogenet Genomics 2015 Aug;25(8):416-26
aDepartment of Systems Pharmacology and Translational Therapeutics, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania Departments of bGenetics cBioengineering, Stanford University Medical Center, Stanford University, Stanford, California, USA.

Assessment of the Radiation Effects of Cardiac CT Angiography Using Protein and Genetic Biomarkers.
JACC Cardiovasc Imaging 2015 Aug 22;8(8):873-84. Epub 2015 Jul 22.
Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California; Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, California; Department of Radiology, Stanford University School of Medicine, Stanford, California. Electronic address:

Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs.
Mayo Clin Proc 2015 Jun;90(6):716-29
Center for Personalized Therapeutics, The University of Chicago, Chicago, IL; Department of Medicine, The University of Chicago, Chicago, IL; Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, IL. Electronic address:

Variations in the binding pocket of an inhibitor of the bacterial division protein FtsZ across genotypes and species.
PLoS Comput Biol 2015 Mar 26;11(3):e1004117. Epub 2015 Mar 26.
Department of Bioengineering, Stanford University, Stanford, California, United States of America; Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, United States of America.

PharmGKB summary: ibuprofen pathways.
Pharmacogenet Genomics 2015 Feb;25(2):96-106
aDepartment of Systems Pharmacology and Translational Therapeutics bInstitute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania Departments of cGenetics dBioengineering, Stanford University, Stanford, California, USA.

PharmGKB summary: gemcitabine pathway.
Pharmacogenet Genomics 2014 Nov;24(11):564-74
Departments of aGenetics bBioengineering, Stanford University, Stanford, California, USA cDepartment of Pharmacotherapy and Translational Research dCenter for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, Florida eDepartment of Molecular Pharmacology & Experimental Therapeutics, Division of Clinical Pharmacology, Mayo Clinic, Rochester, Minnesota, USA.


PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.
Pharmacogenet Genomics 2014 Sep;24(9):464-76
Departments of aGenetics bBioengineering, Stanford University, Stanford, California cACOS for Research, Department of Veterans Affairs Medical Center Departments of dMedicine ePharmacology/Toxicology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.
Pharmacogenet Genomics 2014 Aug;24(8):409-25
Departments of aGenetics bBioengineering, Stanford University, Palo Alto, California cDepartment of Pharmacology and Toxicology and James Graham Brown Cancer Center, University of Louisville, Kentucky, USA dDepartment of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece eDepartment of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden.

PharmGKB summary: tramadol pathway.
Pharmacogenet Genomics 2014 Jul;24(7):374-80
Departments of aGenetics bBioengineering, Stanford University, Stanford, California, USA cDepartment of Anaesthesiology and Pain Medicine, Inselspital dDepartment of Clinical Research, University of Bern, Bern, Switzerland eInstitute of Clinical Pharmacology, University Medical Center, Göttingen, Germany.

Clinical interpretation and implications of whole-genome sequencing.
JAMA 2014 Mar;311(10):1035-45
Stanford Center for Inherited Cardiovascular Disease, Stanford, California2Stanford Cardiovascular Institute, Stanford, California3Division of Cardiovascular Medicine, Stanford University, Stanford, California4Stanford Center for Genomics and Personalized.



PharmGKB summary: isoniazid pathway, pharmacokinetics.
Pharmacogenet Genomics 2016 09;26(9):436-44
Departments of aGenetics bBioengineering, Stanford University, Stanford cKeck School of Medicine of University of Southern California, Los Angeles, California, USA dDepartment of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece eDepartment of Pharmacology, University of Oxford, Oxford, UK.

PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics.
Pharmacogenet Genomics 2017 01;27(1):39-42
Departments of aGenetics bBioengineering, Stanford University, Stanford, California cDepartment of Pediatrics, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio, USA dGenomics England, Queen Mary University of London, London, UK.

PharmGKB summary: voriconazole pathway, pharmacokinetics.
Pharmacogenet Genomics 2017 05;27(5):201-209
Departments of aBiomedical Data Science bBioengineering, Stanford University, Stanford, California cIcahn School of Medicine at Mount Sinai, The Charles Bronfman Institute for Personalized Medicine dDepartment of Medicine, Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai eDepartment of Pharmacy, The Mount Sinai Hospital, New York, New York, USA.


OF